Portugal BioTech Showcase @ JPM week

Pier 9, The Embarcadero,San Francisco CA 94111

11 January, 2023

Description

Join us to get to know the Portuguese Biotech scene, learn how Portugal and the US are working together in this industry, overlook Portugal’s business opportunities, and connect with Portuguese biotech entrepreneurs in the Bay Area. As you may know, Portugal has become very attractive for biotech/pharma companies to open centers there. In May of 2021, Amgen announced it will create 300 highly qualified jobs in Portugal thanks to the opening of a new global center in Lisbon. More recently, Inflammatix, the Bay Area medtech company that develops novel molecular diagnostics for acute infections and sepsis, has been tapping into the local talent pool. And did you know that Portugal is home to fantastic medtech companies such as Sword Health, which November last year raised 163M USD, led by Sapphire Ventures? Don't miss the opportunity to meet some of the most innovative Portuguese biotech startups. Agenda: 3:00-3:15 pm - Registration 3:15-3:20 pm - Welcome Notes Pedro Pinto, Consul General of Portugal in San Francisco3:20-3:40 pm - Portugal BioTech scene and Business Opportunities Teresa Fernandes, Portuguese Trade and Investment Commissioner to the Western USADavid Braga Malta, Pictet Aternative Advisors, and Board Member at Portugal's Biotechnology Industry Organization3:40-4:00 pm - Keynote Speaker: Portugal-US: A partnership to grow Tim Sweeney, Co-Founder & CEO, at Inflammatix, Inc.4:00-4:20 pm - Portuguese BioTech Startups Showcase  CellmAbs - Develops new generation of glyco-immuno-oncology products and personalized therapies for Oncology.CRIAM - Portable in vitro diagnostic company providing rapid analysis for blood diagnostics.iLof - With Patented photonics and AI helps patient-centric drug development.Sensing Future - Designs, develops, and implements medical devices, mainly in Stabilometry/Baropodometry, and Robotics/telemedicine.Targtex - Develops clinical candidates for different oncological indications, most advanced product is focused on Glioblastoma Multiforme (GBM).4:20-5:00 pm - Networking A detailed description of the Portuguese Startups: CellmAbs is a Portuguese biopharmaceutical company, a spin-off from NOVA University of Lisbon, focused on the development of the new generation of glyco-immuno-oncology products and personalized therapies for Oncology. These immunotherapies have the potential to slow tumor growth and elicit an immune response from the patients themselves, with an unprecedented degree of affinity and specificity. CellmAbs has raised a seed stage investment of 1.6M USD in Portugal from Hovione Capital and Portugal Ventures. https://www.cellmabs.com/ CRIAM has developed a fully portable, electricity-independent, easy-to-use, and multi-purpose single-test Point of Care (PoC) diagnostics tool for rapid (3 min), highly accurate (99,79%), automatized (no human error), and affordable blood testing. In addition, CRIAM provides Wi-Fi/5 G connectivity for safe and fast data transfer and a cloud-based data storage system that enables traceability and epidemiological monitoring. With its device-as-a-platform approach, CRIAM aims to become a valuable tool in emergency care, infectious diseases control, nutrition, and veterinary application. CRIAM has raised a seed stage investment of 2 MUSD. https://criamknowledge.com ILof is a digital health company pioneering a breakthrough AI platform to accelerate the future of personalized drug discovery and development. Through advanced AI and Photonics, iLoF is collecting massive amounts of data to build a digital library of biomarkers and biological profiles, bringing together world-class physicists, biologists, and data scientists to get life-saving personalized treatments to patients faster. Recognized by CB Insights as one of the top Digital Health companies in the world and by the Financial Times as a Transformational Business in Healthcare, iLoF is supported by leading institutions like Microsoft Ventures, Mayfield, and Oxford University. https://ilof.tech/ Sensing Future (SFT) was founded in 2011, and designs, develops, and implements medical devices. SFT is a certified company under the standards ISO 9001 and ISO 13485 for medical devices. Main areas of expertise: • Stabilometry/Baropodometry: physical/vestibular rehabilitation, sports medicine, audiology, vertigo. PhysioSensing (physiosensing.net); • Robotics/ telemedicine: ROSE (https://www.youtube.com/watch?v=b-PXUVOqjZY) The company is currently looking to leverage its partnerships in the PhysioSensing products and for an investment partner for its new Robotic assisted tele-echography. https://sensingfuture.com/en/ TargTex is a biotech company focused on the development of clinical candidates for hard-to-treat CNS cancers. Their lead candidate is a selective small molecule, locally delivered through a tailored hydrogel formulation to be applied in the brain cavity left during the tumor resection surgery. The company is planning a global phase 1/2a clinical trial for Q1 2024 in the most aggressive type of primary brain tumor – Glioblastoma. Targtex has raised a seed stage investment of 3 MUSD. https://targtex.com/ Complementary appetizers and drinks will be served.